Cargando…

Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

OBJECTIVE: Concurrent follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) (defined as FL/DLBCL) have been considered an important pathological feature in cell lymphoma. However, clinicopathological information and prognostic factors in these cases are scarce. The aim of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Zhenjie, Zhang, Tingting, Gao, Fenghua, Gong, Wenchen, Cui, Yaoli, Qiu, Lihua, Qian, Zhengzi, Zhou, Shiyong, Meng, Bin, Ren, Xiubao, Li, Lanfang, Wang, Xianhuo, Zhang, Huilai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155961/ https://www.ncbi.nlm.nih.gov/pubmed/35655476 http://dx.doi.org/10.1155/2022/4379556

Ejemplares similares

m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment
por: Zhang, Tingting, et al.
Publicado: (2022)

Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China
por: Gao, Fenghua, et al.
Publicado: (2022)

An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy
por: Lu, Yaxiao, et al.
Publicado: (2021)

A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma
por: Wu, Zizheng, et al.
Publicado: (2021)

PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B‐cell lymphoma
por: Zhang, Huilai, et al.
Publicado: (2022)

A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients
por: Fei, Yue, et al.
Publicado: (2020)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T‐cell lymphomas
por: Zhang, Xuhan, et al.
Publicado: (2019)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma
por: Zhang, Tingting, et al.
Publicado: (2020)

Corrigendum to “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma”
por: Zhang, Tingting, et al.
Publicado: (2021)

Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma
por: Li, Yang, et al.
Publicado: (2021)

Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma
por: Qian, Zhengzi, et al.
Publicado: (2015)

Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer
por: Zhao, Peiqi, et al.
Publicado: (2021)

A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma
por: Qiu, Lihua, et al.
Publicado: (2022)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
por: Grigg, Andrew, et al.
Publicado: (2017)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Pan-Cancer Analysis Reveals Genomic and Clinical Characteristics of TRPV Channel-Related Genes
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Follicular Lymphoma in China: Systematic Evaluation of Follicular Lymphoma Prognostic Models
por: Li, Yanan, et al.
Publicado: (2022)

miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma
por: Wang, Xinyuan, et al.
Publicado: (2020)

Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma
por: Ansell, Stephen M., et al.
Publicado: (2011)

A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

Follicular lymphoma - treatment and prognostic factors
por: Luminari, Stefano, et al.
Publicado: (2012)

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells
por: Dong, Ling, et al.
Publicado: (2016)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

A Phase I Trial to Evaluate the Multiple-Dose Safety and Antitumor Activity of Ursolic Acid Liposomes in Subjects with Advanced Solid Tumors
por: Qian, Zhengzi, et al.
Publicado: (2015)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
Publicado: (2023)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
por: Li, Ru, et al.
Publicado: (2022)

Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy
por: Zhao, Peiqi, et al.
Publicado: (2022)

Concurrent follicular lymphoma and Langerhans cell sarcoma
por: Tashakori, Mehrnoosh, et al.
Publicado: (2021)

The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma
por: Hu, Jiaci, et al.
Publicado: (2023)

Clinical and biological prognostic factors in follicular lymphoma patients
por: Jóna, Ádám, et al.
Publicado: (2022)

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
por: Stathis, Anastasios, et al.
Publicado: (2022)

Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy
por: Maeng, Chi Hoon, et al.
Publicado: (2016)

Novel prognostic tools that identify high-risk follicular lymphoma
por: Luminari, Stefano
Publicado: (2019)

Case Report: Concurrent Occurrence of Abdominal Double Expressor Lymphoma and Jejunum Follicular Lymphoma
por: Takada, Ryutaro, et al.
Publicado: (2021)

Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy
por: Pinto, Antonio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u92mjqh4pj5jljd6i3cm0mvnf3